About Necitumumab
Class: | Monoclonal antibody (EGFR inhibitor)
Use: | Treatment of metastatic squamous non-small cell lung cancer (NSCLC) in combination with gemcitabine and cisplatin
Adult dose: | 800 mg administered intravenously over 60 minutes on days 1 and 8 of a 21-day cycle, in combination with chemotherapy
Pediatric dose: | Safety and efficacy not established in pediatric patients
Side effects: | Rash, hypomagnesemia, diarrhea, fatigue, nausea, vomiting, and infusion-related reactions
Contraind
Drug Class
Monoclonal antibody (EGFR inhibitor)
Uses & Indications
Treatment of metastatic squamous non-small cell lung cancer (NSCLC) in combination with gemcitabine and cisplatin
Storage Requirements
Store refrigerated at 2°C to 8°C (36°F to 46°F); do not freeze; protect from light
Manufacturer & Packaging
Manufacturer: Eli Lilly & Co Inc., U.S.A
Package Size
1 Glass Vial
Price & Supplier
Price in UAE: AED 21403.00
Dosage Information
Adult Dose
800 mg administered intravenously over 60 minutes on days 1 and 8 of a 21-day cycle, in combination with chemotherapy
Pediatric Dose
Safety and efficacy not established in pediatric patients
Side Effects
Rash, hypomagnesemia, diarrhea, fatigue, nausea, vomiting, and infusion-related reactions
Contraindications & Precautions
Hypersensitivity to necitumumab or any component of the formulation; history of severe infusion reactions
Important Warnings
Risk of severe skin reactions, hypomagnesemia, and infusion-related reactions; monitor electrolytes and skin condition during treatment
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice.
Always consult with a licensed healthcare provider or pharmacist in the UAE before taking any medication.
The information presented here is specific to medicines available in UAE pharmacies and is regularly updated
to ensure accuracy for patients and healthcare professionals in the United Arab Emirates.